Novo Nordisk’s obesity drug Wegovy has received approval from the U.S. Food and Drug Administration to treat metabolic dysfunction-associated steatohepatitis (MASH), a common liver disease that affects many individuals with obesity. This latest approval adds to the growing list of conditions for which Wegovy is now authorized to treat.
MASH is a severe form of fatty liver disease that can lead to liver scarring and fibrosis. If left untreated, MASH can progress to cirrhosis, liver cancer, or the need for a liver transplant. The Phase 3 results of Wegovy showed significant improvement in liver scarring and symptom resolution in patients with moderate to advanced liver scarring.
Obesity is a major risk factor for the development of fatty liver disease, making it crucial to address this condition early on to prevent further complications. With the approval of Wegovy for the treatment of MASH, patients now have access to a potentially life-saving therapy that can help improve their liver health and overall well-being.
For more in-depth coverage and analysis of the pharmaceutical industry, including exclusive stories like this one, consider subscribing to STAT+. By becoming a subscriber, you can unlock access to a wealth of valuable information and stay informed about the latest developments in healthcare and medicine.
Don’t miss out on this opportunity to stay ahead of the curve and make informed decisions about your health. Subscribe to STAT+ today and gain access to a world of medical knowledge and expertise.
